Überprüfung…
Automatisch übersetzt. Dosierung und Warnhinweise: bitte im englischen Original prüfen. Auf Englisch lesen
Homepage / Eingetragen in Nigeria / Ietrocare Injection

Ietrocare Injection

NAFDAC Reg.-Nr. A4-100980 Medikament

Registriert bei NAFDAC. Registrierung aktivAs of 1 November 2026 · synced automatically from official sources.
Produkt-
Ietrocare Injection
NAFDAC-Nummer
A4-100980
Wirkstoff
Cetrorelix (Cetrorelix Acetate)
Stärke
0.25 mg/0.5 mL
Form
Solution for injection
VPE:
0.5 mL x 1's (in clear PFS with needle)
Hersteller
Nicht aufgeführt
Applicant (holder)
Ignite Pharma Nigeria Limited
Approved
28 Aug 2024
Status
Active View on NAFDAC ↗
Registration valid to
27 Aug 2029
WER WARNT
None found
Community reports
None
Times checked
0

About the medicine: Cetrorelix: uses, dosage and brands worldwide

What we found

  • Ietrocare Injection is on the NAFDAC register with an active registration (A4-100980). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Ietrocare Injection

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

How to take it and how often
  • Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3
  • The dose of gonadotropins should be adjusted according to individual response
  • Cetrorelix acetate for injection 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase
  • Cetrorelix acetate for Injection 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration
  • When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes
  • No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS)
  • Administration Cetrorelix acetate for Injection 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor
  • Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe: 1
  • Wash hands thoroughly with soap and water. 2
  • Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab. 3
  • Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe. 4
  • Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial. 5
  • Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues
  • Avoid forming bubbles. 6. …
Talk to a doctor first if
  • Cetrorelix acetate for injection is contraindicated under the following conditions: 1
  • Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. 2
  • Known hypersensitivity to GnRH or any other GnRH analogs. 3
  • Known or suspected pregnancy, and lactation (see PRECAUTIONS). 4
  • Severe renal impairment
Warnings

Cetrorelix acetate for injection should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with cetrorelix acetate for injection, pregnancy must be excluded (see CONTRAINDICATIONS and PRECAUTIONS).

Possible side effects

The safety of cetrorelix acetate for injection in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrorelix acetate for injection was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose. Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of cetrorelix acetate for injection treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in cetrorelix acetate for injection treated subjects undergoing COS. …

If you take too much

There have been no reports of overdosage with cetrorelix acetate for injection 0.25 mg or 3 mg in humans. Single doses up to 120 mg cetrorelix acetate for injection have been well tolerated in patients treated for other indications without signs of overdosage.

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-08-08.

Label for cetrorelix (cetrorelix acetate), the active ingredient registered with NAFDAC.

Check your pack of Ietrocare Injection

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Ietrocare Injection

What is in Ietrocare Injection?

Ietrocare Injection contains Cetrorelix (Cetrorelix Acetate) (0.25 mg/0.5 mL), as solution for injection, according to its NAFDAC registration record.

Is Ietrocare Injection registered with NAFDAC?

Yes. Ietrocare Injection is listed on the NAFDAC register under registration number A4-100980, and its registration is active as of 1 November 2026.

Has Ietrocare Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Ietrocare Injection in our automatically synced alert list.

How can I check that my pack of Ietrocare Injection is genuine?

Run a free authenticity scan with the NAFDAC number A4-100980, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Ietrocare Injection?

Follow your prescription or the leaflet in your pack. The official label says: Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrorelix acetate for injection 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase. Cetrorelix acetate for Injection 0.25 mg is administered on either stimulation da…

What is Ietrocare Injection used for?

Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. (Summarised from the official U.S. FDA label for cetrorelix (cetrorelix acetate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Ietrocare Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.